MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF

MESOBLAST LTD

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026

$11.95−1.33 (-10.02%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Dividends

Mesoblast has not reported a dividend

No dividend per share appears in Mesoblast's annual filings since fiscal 2015.

Where these numbers come from

Parsed from the XBRL in Mesoblast's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on Jan 10, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MESO.

Revenue growth599.2% · median 4.8%

Gross margin86.1% · median 69.7%

Net margin-47.8% · median -246.6%

Company	Revenue	Growth
MESO	$120.25M	+599.2%
CRSP	$13.39M	-64.8%
LCTX	$13.08M	+19.9%
ELUT	$12.14M	-0.3%
CRBU	$10.04M	+10.0%
ZEOX	$6.99M	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: June 30
Employees: 108
Auditor: PricewaterhouseCoopers
SEC CIK: 1345099

Advertisement
300 × 250